Runx2 Induces Bone Osteolysis by Transcriptional Suppression of TSSC1
Overview
Authors
Affiliations
Advanced breast cancers frequently metastasize to bone, resulting in osteolytic lesions, however, the underlying mechanisms are poorly understood. Runx2, a bone-specific transcriptional factor, is abnormally expressed in highly metastatic breast cancer cells. Here, we found that TSSC1 inhibits breast cancer cell invasion. Subsequently, TSSC1 is confirmed as a target of Runx2 and is negatively regulated by Runx2. Furthermore, overexpression of Runx2 induces bone osteolysis in a TSSC1-dependent manner. Our results may provide a strategy for the treatment of breast cancer and the prevention of skeletal metastasis.
Ognibene M, Amoroso L, Melchionda F, Cangelosi D, Zara F, Parodi S Cancers (Basel). 2021; 13(22).
PMID: 34830942 PMC: 8616235. DOI: 10.3390/cancers13225792.
Dungan J, Qin X, Hurdle M, Haynes C, Hauser E, Kraus W Front Genet. 2021; 12:661497.
PMID: 34140969 PMC: 8204081. DOI: 10.3389/fgene.2021.661497.
Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment.
Jeong H, Cho S, Park S Endocrinol Metab (Seoul). 2016; 31(4):485-492.
PMID: 28029019 PMC: 5195822. DOI: 10.3803/EnM.2016.31.4.485.
TSSC1 is novel component of the endosomal retrieval machinery.
Gershlick D, Schindler C, Chen Y, Bonifacino J Mol Biol Cell. 2016; 27(18):2867-78.
PMID: 27440922 PMC: 5025273. DOI: 10.1091/mbc.E16-04-0209.